U.S. Federal Judge Rules for Sanofi, Regeneron in Long-Running Patent Dispute; Amgen to Appeal
August 28 2019 - 6:34PM
Dow Jones News
By Maria Armental
A U.S. federal judge handed a partial victory to Sanofi and
Regeneron Pharmaceuticals Inc. in a long-running patent dispute
with Amgen Inc.
The judge ruled that Amgen's patent claims for antibodies
targeting PCSK9 were invalid based on lack of enablement,
overturning portions of a jury verdict that had upheld the validity
of three claims.
"Amgen's patents are overly broad and invalid," Joseph LaRosa,
Regeneron's general counsel, said in a statement. "Praluent was
developed using Regeneron's proprietary science and technology and
the judge has confirmed our position by issuing this ruling."
Amgen said it planned to appeal.
"We disagree with the Court's decision in reversing the jury
verdict on enablement and will seek review by the appellate court,"
Amgen wrote. "Protecting intellectual property is critical to our
business since it allows for our investment in the research and
development of new medicines."
Amgen sued in 2014 trying to block the sale of Praluent, which
Sanofi and Regeneron jointly developed.
Praluent and Amgen's Repatha were approved for sale in the U.S.
in 2015. They are both part of a powerful drug class that promises
help for patients who have struggled to control their cholesterol
using older statin medicines.
The drugs target a protein called PCSK9 that interferes with the
body's ability to clear artery-damaging cholesterol from the
blood.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
August 28, 2019 18:19 ET (22:19 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024
